Allosteric EGFR inhibitors and methods of use thereof
US12377080B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 19, 2020 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Dec 3, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to a compound of Formula (I), which acts as an allosteric inhibitor of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compound; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.